As of Apr 21
| +0.01 / +0.32%|
The 8 analysts offering 12-month price forecasts for Cardiome Pharma Corp have a median target of 6.95, with a high estimate of 9.50 and a low estimate of 3.50. The median estimate represents a +121.34% increase from the last price of 3.14.
The current consensus among 8 polled investment analysts is to Buy stock in Cardiome Pharma Corp. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.